Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Active not recruiting 3Recruiting 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 123Recurrence 12Neoplasms 8Immunoglobulin Light-chain Amyloidosis 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Neoplasms, Plasma Cell 5Smoldering Multiple Myeloma 4Lymphoma 4Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 3Leukemia, Lymphocytic, Chronic, B-Cell 3Plasmacytoma 2Plasmablastic Lymphoma 2Neoplasm, Residual 2Myelodysplastic Syndromes 2Hodgkin Disease 2Hematologic Neoplasms 2Amyloidosis 2Acute Kidney Injury 2Triple Negative Breast Neoplasms 1Proteostasis Deficiencies 1Primary Myelofibrosis 1Paraproteinemias 1Non-small Cell Lung Cancer With STK11/LKB1 Mutation 1Microsatellite Unstable Colorectal Cancer 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Plasma Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Dexamethasone 17Lenalidomide 15Bortezomib 12Cyclophosphamide 7fludarabine 6carfilzomib 6Melphalan 6daratumumab 5Calcium Dobesilate 5pomalidomide 3gamma-Globulins 3fludarabine phosphate 3belantamab mafodotin 3Whole-Body Irradiation 3Trimethoprim, Sulfamethoxazole Drug Combination 3Tacrolimus 3Mycophenolic Acid 3isatuximab 2elotuzumab 2Sirolimus 2Prednisone 2Immunoglobulins, Intravenous 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Ciprofloxacin 2Amoxicillin-Potassium Clavulanate Combination 2venetoclax 1thymoglobulin 1siltuximab 1poly ICLC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × daratumumab × 1 year × Clear all
NCT03500445 2026-04-13

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

University of Chicago

Phase 2 Active not recruiting
75 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04151667 2026-03-11

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
33 enrolled 11 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05182073 2025-12-12

FT576 in Subjects With Multiple Myeloma

Fate Therapeutics

Phase 1 Completed
31 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07075510 2025-10-29

Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders

University of Maryland, Baltimore

Phase 1/2 Recruiting
30 enrolled
Plasma cell

Neoplasms, Plasma Cell

NCT04052880 2025-07-20

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

Icahn School of Medicine at Mount Sinai

Phase 2 Active not recruiting
17 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡